trending Market Intelligence /marketintelligence/en/news-insights/trending/Ln9DErqFdxoSKCHWp6Zhxg2 content esgSubNav
In This List

Abattis Bioceuticals to acquire Green Tree Therapeutics

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Abattis Bioceuticals to acquire Green Tree Therapeutics

Medical cannabis company Abattis Bioceuticals Corp. is looking to acquire Green Tree Therapeutics, which sells vaporizers across North America.

The company has entered a nonbinding agreement to buy Winston Resources Inc., which owns Green Tree Therapeutics.

Abattis plans to issue 5.5 million of its shares to Green Tree shareholders and another 25 million shares to Winston Resources as consideration for the purchase.

The Green Tree Therapeutics buy will help provide Abattis with an entry point into the vaporizers market, the company's CEO, Rob Abenante, said in a statement.